New Oral GLP-1 Drug Shows Promise for People With Early Type 2 Diabetes

GLP-1-based medicines have become an important part of modern diabetes treatment, but many currently available therapies require injections. Researchers are therefore investigating oral alternatives that could make treatment easier for some patients.

A randomized, double-blind, placebo-controlled clinical trial published in Nature Medicine evaluated safiglipron, an oral small-molecule GLP-1 receptor agonist, in people with early type 2 diabetes.

The research examined its effects on blood glucose control and metabolic measures while also monitoring side effects. Oral GLP-1 treatments could potentially expand treatment options for people who find injectable medication difficult or inconvenient.

However, the emergence of a new oral treatment does not mean that existing diabetes medicines should be stopped or changed without medical advice. Treatment decisions depend on blood-glucose levels, kidney and cardiovascular health, other medications, weight, side effects and individual treatment goals.

The study adds to the rapidly developing field of diabetes treatment and demonstrates the continuing search for easier and more effective ways to control type 2 diabetes.